The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer
โ Scribed by Nelson, Robert L.
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 603 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
The pharmacokinetics of vindesine, vincristine, and vinblastine were investigated in patients with cancer. All drugs were administered rapidly via intravenous injection, and drug levels were determined in serum obtained at intervals after injection by radioimmunoassay. All three drugs exhibited a triphasic serum decay pattern, with no major differences in alpha or beta phase halfโlives noted among them. However, vincristine had a longer and more variable terminal phase halfโlife (85 ยฑ 69 hr) than vindesine (24 ยฑ 10 hr) or vinblastine (25 ยฑ 7 hr). Central compartment volumes were also different. The most important finding was the observation of differences in the serum or body clearances of these drugs (vincristine 0.106 liter/ kg/hr, vindesine 0.252 liter/kg/hr, and vinblastine 0.740 liter/kg/hr). These differences correlate well with the results of similar studies done in animals, with acute LD~50~ data in mice, and with the usually employed weekly clinical doses for these drugs. These findings support the hypothesis that differences in the toxicities of these alkaloids may be related in part to differences in their pharmacokinetics.
๐ SIMILAR VOLUMES
A combination of actinomycin D and vincristine has been used to treat 92 patients with various kinds of cancer. The best results were obtained in patients with lung cancer, with a n initial response rate of 6096 and an average duration of remission of over 8 months. Some patients with sarcomas and m
## Abstract ## BACKGROUND Vincristine (VCR) is widely used to treat patients with malignant disease; among the patients treated with VCR are children with brain tumors. In vitro studies have demonstrated that the cytotoxic activity of VCR is related to both extracellular concentration and duration
## Abstract We assessed whether split dosing with the methylating agent DTIC is an effective strategy for inactivating the DNA repair protein __O__6โalkylguanine DNAโATase in order to decrease tumour resistance to BCNU. ATase levels in PBMCs were used as a surrogate for tumour ATase depletion to de